Skip to main content

Table 4 Impact of Medicare Part D on antidementia prescriptions filled annually among beneficiaries with any antidementia drug use pre-part D (n = 1,197) by drug category

From: The impact of Medicare prescription drug coverage on the use of antidementia drugs

Pharmacy benefit group Mean No. (SD) of pre–part d prescriptions Mean No. (SD) of post–part d prescriptions Adjusted ratio* of pre–part D vs. Post–part d prescriptions Comparison of the adjusted ratio* of the no-coverage, $150-cap, and $350-cap groups with that of the no-cap group
  Ratio (95% CI) P Value Ratio (95% CI) P Value
Cholinesterase inhibitors
No coverage group 3.87 (4.53) 5.44 (5.33) 1.40 (1.13-1.73) 0.0022 1.28 (1.02-1.61) 0.0323
$150 cap group 4.64 (4.71) 5.90 (5.27) 1.27 (1.05-1.53) 0.0125 1.16 (0.95-1.42) 0.1410
$350 cap group** 4.92 (4.68) 6.24 (5.32) 1.26 (1.18-1.34) <0.0001 1.15 (1.05-1.27) 0.0040
No cap group** 6.45 (5.27) 7.09 (5.59) 1.09 (1.01-1.18) 0.0280 [Reference]
Namenda®
No coverage group 1.92 (3.57) 4.86 (5.46) 2.50 (1.98-3.16) <0.0001 1.26 (0.97-1.66) 0.0884
$150 cap group 1.27 (2.87) 3.09 (4.73) 2.38 (1.74-3.25) <0.0001 1.20 (0.85-1.69) 0.2959
$350 cap group 1.37 (3.05) 3.24 (4.88) 2.33 (2.06-2.64) <0.0001 1.18 (098.-1.41) 0.0816
No cap group 1.97 (3.74) 3.95 (5.15) 1.98 (1.73-2.27) <0.0001 [Reference]
  1. Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; SD, standard deviation.
  2. * Analyses were adjusted for sex; age; census-block group-level data concerning race, status below poverty line, residence; health status data (binary variables for congestive heart failure, depression, diabetes, hypertension, and ischemic heart disease); and prospective risk score.
  3. α Aricept® andExelon®.
  4. ** Aricept®, Razadyne, and Exelon®.